Evidence map›Paper›PMID 37496194›Full record

ArticleFEMS yeast research2023

Production of Rhizopus oryzae lipase using optimized Yarrowia lipolytica expression system.

Lea Vidal, Zehui Dong, Kim Olofsson, Eva Nordberg Karlsson, Jean-Marc Nicaud

Abstract read
In one paragraph

Article in FEMS yeast research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lea VidalINRAE, AgroParisTech, Micalis Institute, Université Paris-Saclay, 78350 Jouy-en-Josas, France.ORCID 0000-0001-8896-2949
Zehui DongBiotechnology, Department of Chemistry, Lund University, 221 00 Lund, Sweden.ORCID 0000-0001-6750-5183
Kim OlofssonAAK AB, Skrivaregatan 9, 215 32 Malmö, Sweden.ORCID 0000-0001-7426-5499
Eva Nordberg KarlssonBiotechnology, Department of Chemistry, Lund University, 221 00 Lund, Sweden.ORCID 0000-0002-8597-7050
Jean-Marc NicaudINRAE, AgroParisTech, Micalis Institute, Université Paris-Saclay, 78350 Jouy-en-Josas, France.ORCID 0000-0002-6679-972X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Yarrowia lipolytica is an alternative yeast for heterologous protein production. Based on auto-cloning vectors, a set of 18 chromogenic cloning vectors was developed, each containing one of the excisable auxotrophic selective markers URA3ex, LYS5ex, and LEU2ex, and one of six different promoters: the constitutive pTEF, the phase dependent hybrid pHp4d, and the erythritol-inducible promoters from pEYK1 and pEYL1 derivatives. These vectors allowed to increase the speed of cloning of the gene of interest. In parallel, an improved new rProt recipient strain JMY8647 was developed by abolishing filamentation and introducing an auxotrophy for lysine (Lys-), providing an additional marker for genetic engineering. Using this cloning strategy, the optimal targeting sequence for Rhizopus oryzae ROL lipase secretion was determined. Among the eight targeting sequences, the SP6 signal sequence resulted in a 23% improvement in the lipase activity compared to that obtained with the wild-type ROL signal sequence. Higher specific lipase activities were obtained using hybrid erythritol-inducible promoters pHU8EYK and pEYL1-5AB, 1.9 and 2.2 times, respectively, when compared with the constitutive pTEF promoter. Two copy strains produce a 3.3 fold increase in lipase activity over the pTEF monocopy strain (266.7 versus 79.7 mU/mg).

Indexed as

YarrowiaErythritolFungal ProteinsLipaseRhizopus oryzaeErythritolFungal ProteinsLipaseexpression systemsexpression vectorinducible promoterlipaseprotein secretionYarrowia lipolytica

Identifiers

PMID37496194
PMCPMC10384013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.